SARASOTA — A new contract with Marathon Medical Inc. is expected to have a dramatic impact on a Sarasota-based skin health company’s sales force.
As such that Marathon is a primary distributor for VA hospitals and medical facilities, Omeza LLC Director of Sales – East Region Jim McSweeney says in a statement that the contract will allow Omeza to quickly scale up its internal VA sales force.
“Marathon is very well known,” he says. “They will open doors for us, including within the VA and Department of Defense, expediting the availability of Omeza products to patients nationwide.”
The company distributes medical and surgical devices, drugs, supplies and related apparatus. Under Marathon’s Federal Supply Schedule/General Services Administration contract, Omeza will be able to sell Omeza Collagen Matrix, Omeza Lidocaine Lavage and Omeza Skin Protectant to VA hospitals and clinics, Indian Health Service hospitals and clinics, and other federal agencies.
“We are excited to be partnering with a great organization like Omeza,” says John St. Leger, founder of Marathon Medical, in the release. “The product offering and vision are excellent, and we share common values and goals to support Veterans and Vet-owned businesses. We are looking forward to helping them grow the market.”
The collagen matrix product recently was cleared through the FDA 510(k) premarket notification process.
Also earlier this year, Omeza closed on the sale of $5 million of convertible notes to 22 current and six new investors. With the sale, the skin health company’s total investment totaled $13 million, all of it from individuals. The company’s goal is to raise $20 million for the Series A capital raise. The Series A round likely will be the company’s first institutional round of funding, according to a statement.
Omeza is a skin health and tissue regeneration company dedicated to equitable access to better wound care outcomes for all patients at all sites of care, reducing the rate of non-traumatic lower extremity amputations, hospitalizations due to skin infections and recurrence of chronic leg and foot wounds.